Novel electrocardiographic biomarkers to distiguish benign from malignant drug-induced QT prolongation combined simulation and clinical study
Ended Purchase Order Awarded Last action
- Contract number
- HHSF223201400209A
- Awardee
-
Frontage Laboratories, Inc. UEI CSMHKH3DKHH8
- Awarding agency
-
Food and Drug Administration
Department of Health and Human Services
- Obligated
- $137,670
Award facts
- Contract value 100% obligated
- $137,670.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541711 Research and Development in Biotechnology
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Exton, PA 19341, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Change Order | $32,710 | |
| Original award | $104,960 |
Quick answers
Who was awarded contract HHSF223201400209A?
HHSF223201400209A was awarded to Frontage Laboratories, Inc. by Food and Drug Administration (Department of Health and Human Services) on July 15, 2014.
How much is contract HHSF223201400209A worth?
The government has obligated $137,670 on HHSF223201400209A.
Was contract HHSF223201400209A competed?
The extent of competition for HHSF223201400209A was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award